Accordingly, we recently identified synovial markers of response to methotrexate, TNF blockade, tocilizumab or rituximab therapy in patients with established RA, a demonstration that a “molecular” diagnosis and characterization of arthritis can lead to specific and clinically relevant decisions [14, 15, 19, 20]. Here, TNF is linked to arthritic joint disease.